MAPT and amyloidosis: Additionally, clinical subsampling for stage‐wise representative Braak tau and Thal (amyloid plaque) phases will give insight into the extent to which high abnormal proteinaceous burden indicating AD co‐pathology may influence our reported mtDNA findings, or whether the profile discerned here is LBD‐specific.